In these two podcasts, medical experts and a patient representative share their perspectives on new Primary Biliary Cholangitis (PBC) data from EASL 2023.
In podcast 1, physicians Dr Emma Culver and Prof. Gideon Hirschfield discuss the evidence of cancer risk associated with PBC, how liver stiffness progression is associated with prognosis; and outcomes and response prediction in second-line therapy.
In podcast 2, CEO of the PBC Foundation, Robert Mitchell-Thain, and autoimmune specialist nurse Kath Houghton explore the impact of PBC symptoms and new instruments for assessing them. They also discuss data highlighting the importance of the current move toward normalisation of liver biomarkers and take a look at some early data on future therapies and therapeutic targets.
Transcripts, with details of the presentations covered, are available for download.
When treating people living with PBC, the goal is to aim for normal liver blood tests and normal quality of life
Emerging therapies are hoped to both significantly address biochemical and symptom control in PBC
Pruritus and fatigue can be devastating, and upcoming trials importantly are addressing alleviation of patient symptom burden as a priority
In the expected future treatment landscape, optimised markers of prognosis, response, and quality of life will become increasingly important